Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Shanghai Hengrui Pharmaceutical Co: Clinical Trials & FDA Approval Profile

Shanghai Hengrui Pharmaceutical Co (Global / Institutional) sponsors 37 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 17 active protocols (15 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)8.1%
Median Closed Enrollment vs National (145 pts)89 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Shanghai Hengrui Pharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)37
Active Pipeline (Recruiting Now)17 (15)
Completed vs Stopped Early8 / 3 (8.1%)
Median Closed Actual Enrollment89 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Shanghai Hengrui Pharmaceutical Co
Hospital Research SiteLocationShared Protocols
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong4
Beijing Cancer HospitalBeijing, Beijing Municipality3
Guangdong Provincial People's HospitalGuangzhou3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Shanghai Hengrui Pharmaceutical Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05376904A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy.Phase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Shanghai Hengrui Pharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI